{"id":324468,"date":"2025-10-22T18:16:13","date_gmt":"2025-10-22T18:16:13","guid":{"rendered":"https:\/\/www.europesays.com\/us\/324468\/"},"modified":"2025-10-22T18:16:13","modified_gmt":"2025-10-22T18:16:13","slug":"cvs-caremark-tells-aids-activists-gilead-needs-to-lower-the-price-of-its-new-hiv-drug-to-get-on-formularies","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/324468\/","title":{"rendered":"CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies"},"content":{"rendered":"

For the past three months, CVS Caremark has resisted adding a new Gilead Sciences HIV prevention drug to its formularies, repeatedly explaining there are \u201cclinical, financial, and regulatory considerations\u201d that must be reviewed before it will take that step.<\/p>\n

Not surprisingly, though, what the largest pharmacy benefits manager in the U.S. simply wants is a much lower price, according to email sent this week by a company executive to an AIDS patient advocacy group.<\/p>\n

At issue is Yeztugo, a groundbreaking medicine that was approved last June<\/a> by the U.S. Food and Drug Administration. Clinical trials showed the twice-a-year injectable was highly effective in preventing the infectious disease, prompting enthusiasm about combating HIV globally. But the $28,000 price tag in the U.S. has raised concern about affordability.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"For the past three months, CVS Caremark has resisted adding a new Gilead Sciences HIV prevention drug to…\n","protected":false},"author":3,"featured_media":324469,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[47230,210,1141,1142,10940,152,153,881,154,67,132,68],"class_list":{"0":"post-324468","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health-care","8":"tag-drug-prices","9":"tag-health","10":"tag-health-care","11":"tag-healthcare","12":"tag-hiv-aids","13":"tag-pharmaceuticals","14":"tag-policy","15":"tag-public-health","16":"tag-stat","17":"tag-united-states","18":"tag-unitedstates","19":"tag-us"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/324468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=324468"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/324468\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/324469"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=324468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=324468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=324468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}